Kyle Blackburn, MD
Neurology · Dallas, TXNPI 1144640533
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,725 of the $13,833 with a category attached, or 70.3%. 8 manufacturers reported payments, led by TG Therapeutics, Inc. at 45.5% of the total. Reporting peaked in 2023 at $6,662 and has fallen 95.9% since, to $270 in 2025.
Across 17 payments — averaging $813.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$6K
- EMD Serono, Inc.$5K
- Genentech USA, Inc.$2K
- UCB, Inc.$206
- AstraZeneca$175
- Biogen$150
- plus $213 from 2 others
Across 11 payments — averaging $7493.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$68K
- F. Hoffmann-la Roche AG$14K
What the payments were for
- Consulting fees$9,72570%
- Travel & lodging$3513%
- Food & beverage$7896%
- Education$2,96821%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 5 | $6,296 |
| EMD Serono, Inc. | 4 | $4,773 |
| Genentech USA, Inc. | 1 | $2,020 |
| UCB, Inc. | 2 | $206 |
| AstraZeneca | 1 | $175 |
| Biogen | 1 | $150 |
| Amgen | 2 | $112 |
| Genentech, Inc. | 1 | $101 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,833 in reported general payments places this provider in the 75th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 61 | $557,544 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 24 | $291,225 |
| Nurtec OdtRimegepant Sulfate | 18 | $23,212 |
| Dalfampridine ErDalfampridine | 26 | $9,318 |
| Mycophenolate Mofetil | 35 | $5,085 |
| Gabapentin | 30 | $1,158 |
| Propranolol Hcl ErPropranolol Hcl | 11 | $1,096 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $1,046 |
| Pregabalin | 21 | $1,013 |
| Baclofen | 25 | $670 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $479 |
| Diazepam | 16 | $198 |
| Prednisone | 27 | $193 |
| Clonazepam | 28 | $189 |
| Ondansetron Hcl | 15 | $156 |
Paid to pharmacies, not to this prescriber.
Other neurology in Dallas
- Nirav PavasiaDallas$1.4M
- Benjamin GreenbergDallas$773K
- Waleed El-FekyDallas$587K
- Adnan SubeiDallas$477K
- Steven HerzogDallas$461K
- Priyanka ChaudhryDallas$329K
- Deborah FriedmanDallas$284K
- Mark AlbertsDallas$212K
- Aanchal TanejaDallas$169K
- Salman BhaiDallas$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.